BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.91 USD | -1.53% |
|
-8.71% | -16.09% |
ETFs positioned on BioMarin Pharmaceutical Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | -5.79% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - | |
| 0.83% | 16 M€ | -8.49% | ||
| 0.77% | 4 M€ | +20.15% | ||
| 0.47% | 267 M€ | +5.99% | ||
| 0.44% | 18 M€ | +3.79% | - | |
| 0.20% | 9 M€ | +15.45% | - | |
| 0.19% | 9 M€ | -.--% | - | |
| 0.09% | 736 M€ | +6.09% | ||
| 0.09% | 9 M€ | +2.75% | - | |
| 0.07% | 276 M€ | +11.40% | - | |
| 0.07% | 2,510 M€ | +12.00% | ||
| 0.06% | 9 M€ | +6.26% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 7 M€ | +0.11% | - | |
| 0.05% | 277 M€ | -.--% | - | |
| 0.05% | 194 M€ | +7.48% | - | |
| 0.05% | 441 M€ | +10.26% | ||
| 0.04% | 26 M€ | +16.85% | - | |
| 0.04% | 35 M€ | +9.63% | - | |
| 0.04% | 2,658 M€ | +10.56% | - | |
| 0.03% | 205 M€ | -.--% | ||
| 0.03% | 273 M€ | +15.83% | ||
| 0.03% | 206 M€ | -.--% | ||
| 0.03% | 607 M€ | +0.05% | - |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
80.91
USD
Average target price
110
USD
Spread / Average Target
+35.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.09% | 15.35B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- BMRN Stock
- Funds and ETFs BioMarin Pharmaceutical Inc.
